Anoro ellipta used for?

Anoro Ellipta is used for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1]. It is also used to reduce exacerbations of COPD [1].

What is in Anoro Ellipta?

Anoro Ellipta is a combination medication containing umeclidinium and vilanterol [1]. Umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta2-adrenergic agonist (LABA) [1].

How does Anoro Ellipta work for COPD?

Umeclidinium works by relaxing the muscles around the airways in the lungs, which helps to open the airways and make breathing easier [1]. Vilanterol works by relaxing the muscles in the airways, also helping to improve airflow [1]. Together, these actions help to manage the symptoms of COPD and prevent flare-ups [1].

When does Anoro Ellipta's patent protection expire?

The patent expiration dates for Anoro Ellipta vary depending on the specific patent. DrugPatentWatch.com provides detailed information on Anoro Ellipta's patent landscape [2]. Generally, the loss of patent exclusivity can open the door for generic competition.

Can I use Anoro Ellipta for asthma?

Anoro Ellipta is not indicated for the treatment of asthma [1]. Its use is specifically approved for COPD management.